Background and Aim: The aim of this survey was to find out the patients' perspectives concerning biosimilars. Methods: An online survey consisting of 14 questions was made available between November 2014 and October 2015. Only respondents who had heard of biosimilars were asked to respond the final twelve questions. Results: A total of 1181 patients responded. Of these, 38% had heard of biosimilars. The respondents worried about biosimilars' safety profile [47.0%], efficacy [40.3%], and molecular basis [35.0%]. Only 25.2% of the respondents had no concerns about biosimilars. Just over half [55.9%] of the respondents thought that the lower cost of the biosimilars should not come before their safety and efficacy. Only 12.5% of respondents felt that extrapolation made sense. The survey showed that 39.9% felt that patients should be systematically informed, and 26.7% felt that patient associations should be informed and able to give their opinions. It also revealed that 20.9% of the respondents would be against the idea of interchangeability if the patient was not aware; 65.7% of the respondents would want to know whether they were receiving the reference drug or the biosimilar, and have all necessary information in writing before the drug was administered. Only 31.0% of the respondents would be fully confident about biosimilars, even if they were prescribed and explained by the treating physician. Conclusions: Most patients were not familiar with biosimilars, and those who were had doubts and concerns about the biosimilars' safety and efficacy. The patients wished to be informed and involved in decision-making concerning biosimilars.
Introduction
Inflammatory bowel disease [IBD] is a chronic and disabling condition. 1, 2 Anti-Tumour Necrosis Factor [TNF] therapy [infliximab, adalimumab, golimumab] has changed the treatment of IBD refractory to standard medications. 3 Anti-TNF therapy is increasingly used to treat IBD in clinical practice. In a French referral centre, the percentages of ulcerative colitis and Crohn's disease patients exposed to anti-TNF therapy were 29.0% for infliximab and 64.7% in total at 5 years from the time of diagnosis, respectively. 4, 5 Interestingly, a Dutch study showed that health care costs caused by IBD have shifted from hospitalization and surgery-related costs to medication costs [most importantly, anti-TNF therapy]. 6 Biosimilars are now available in clinical practice to IBD patients in several countries around the world. Biosimilars are highly similar copies of previously approved original biologic medicines whose data patent protection has expired. 7 Biosimilar infliximab was the first biosimilar monoclonal antibody approved by the European Medicines Agency. 8 However, some concerns have been raised about the safety and efficacy of biosimilar medicines by both physicians and patients. In 2014, a first survey was published that evaluated awareness of biosimilar monoclonal antibodies among IBD specialists, and their readiness to use such therapies. 9 The survey showed that most IBD experts had a good understanding of biosimilars; however, some still had a misconception of biosimilars being generic copies of the original biologic agents. 9 A recent update of this survey showed that there were fewer concerns and more confidence among IBD specialists about using biosimilars in clinical practice. 10 In contrast, the patients' perspectives concerning biosimilars has been unknown.
The purpose of the Biologics and Biosimilars survey was to assess patients' knowledge about biosimilars, to find out how aware patients are of the issues involving biosimilars, and to gain information to serve as a basis for a common European Federation of Crohn's and Ulcerative Colitis Association [EFCCA] position in order to effectively advocate for better patients' rights with the medicine licensing authorities and relevant government institutions. To our knowledge, this is the first such survey about patient perspectives concerning biosimilars.
The Survey

The questionnaire
The questionnaire [see Supplementary Data] was developed by EFCCA in collaboration with experts in the field [Laurent PeyrinBiroulet, Xavier Roblin, Silvio Danese, and Luisa Avedano], and it consisted of 14 questions. A pilot questionnaire was first administered to 35 IBD patients. As a direct result of this pilot survey, minor modifications were made in order to improve understanding of the questions and to eliminate possible sources of confusion.
The final questionnaire was then available online from November 2014 to October 2015 on the website of EFCCA. The national patient associations were responsible for informing their members about the survey. After basic demographic questions, only those respondents who had previously heard of biosimilars continued to the biosimilarspecific questions. The questionnaire [see Supplementary Data] was made available in nine languages [English, French, Italian, German, Spanish, Russian, Greek, Turkish, and Hebrew].
The participants
The participants of the survey were members of EFCCA member associations as well as members of Agora [a platform of organizations of people with rheumatic diseases in southern Europe]. The recruitment was self-selective.
Statistical considerations
The response variables were categorical. Explanatory variables were integer age and binary disease. A binary logit model was used for the response variables that had only two possible values and a generalized logit model for the variables that had more than two possible values. In the case that the age or disease variable was not statistically significant, the variable with the greater p-value was removed from the model. 
Patient views on biosimilars
Exposure to biologics and biosimilars [Questions 1-2]
Question 1 was about current and previous exposure to anti-TNF therapy, while question 2 asked patients whether they had heard of biosimilars. Of the respondents, 52.9% of Crohn's disease [later referred to as CD] patients and 32.3% of ulcerative colitis [later referred to as UC] patients were currently treated with anti-TNF; 6.9% of all respondents had received anti-TNF in the past, but the therapy had been discontinued due to inefficacy, and 7.0% had received anti-TNF in the past, but the therapy was discontinued due to side effects.
Of the respondents, 36.6% of Crohn's disease patients and 35.5% of ulcerative colitis patients had heard of biosimilars. Only these respondents [n = 383] continued the survey to the biosimilarspecific questions.
Concerns about biosimilars [Question 3]
The most common biosimilar-related concerns among the respondents were safety and efficacy: 46 
Lower price of biosimilars [Question 4]
When asked about the possible lower price of biosimilars in comparison with the reference drug, 54.6% of the respondents were of the opinion that the cost of treatment should not come before the effectiveness or safety and tolerance of the medicine [56.3% of respondents with CD, 51.8% of respondents with UC]. Moreover, 31.3% of the respondents believed that more patients would be treated with biologics due to the lower price [30.0% of respondents with CD, 33.6% of respondents with UC]; 5.2% of the respondents 
Extrapolating data [Question 5]
The respondents were told that the biosimilar of Remicade® was approved for the treatment of IBD by extrapolating data from rheumatoid arthritis, and asked how they felt about this-30 
Biosimilars coming onto the market [Question 6]
Of the respondents, 42.8% thought that patients should systematically be given information about biosimilars [41.7% of respondents with CD, 44.8% of respondents with UC], and 25.1% thought that patient associations should be informed and able to give their opinion on biosimilar-related matters [25.8% of respondents with CD, 23.8% of respondents with UC]. Furthermore, 22.7% of the respondents thought that biosimilars should be given to many more patients in a real-life setting before recommending their use in large patient populations [23.8% of respondents with CD, 21.0% of respondents with UC], and 8.1% of the respondents thought that the country in which the biosimilar drug had been tested or created should be known before the biosimilar was used in their own country [6.7% of respondents with CD, 10.5% of respondents with UC]. There were no statistically significant differences between illnesses or ages, and the results can be seen in Table 1 .
Interchangeability with reference drug [Question 7]
Respondents were told that in the future, biosimilars could be interchangeable with the reference drug. Of these respondents, 30.0% would accept the exchange if their treating physician approved it Overall IBD population n = 383
Crohn's disease n = 240 Ulcerative colitis n = 143 
Same pharmacological name [Question 8]
The respondents were told that the biosimilars would have the same pharmacological name as the reference drug, so that when prescribed, there would be no way to distinguish it from the reference drug. In response, 44.1% of the respondents said they would want to know whether they were receiving the biosimilar or the reference drug [45.4% of respondents with CD, 42.0% of respondents with UC], and 20.9% of the respondents would want to have all the necessary information before the drug was administered, and obtain written information, e.g. a card, to be used for future care [20.8% of respondents with CD, 21.0% of respondents with UC]; 22.2% would not mind not being able to distinguish use of the biosimilar from that of the reference drug as long as the biosimilar had the same efficacy and safety profile as the reference drug [20.8% of respondents with CD, 24.5% of respondents with UC], and 11.7% of the respondents would like to be informed, but would trust their pharmacist or treating physician [11.3% of respondents with CD, 12.6% of respondents with UC]. There were no statistically significant differences between illnesses or ages, and the results can be seen in Table 1 .
Biosimilars' impact on the management of IBD [Question 9]
Of the respondents, 12.0% believed that biosimilars would completely impact the management of IBD [9 
Discussion
This is the first survey addressing patient perspectives on biosimilar medications. One of the most striking findings was the unfamiliarity of the respondents with biosimilars. Although 45.0% of the respondents were currently treated with biologic medications, only 36.2% had heard of biosimilars. This would mean that even some of the patients who were receiving biologic medications had not been told about biosimilars that might be considered as alternative treatments for them in the future.
As well as not being informed about biosimilars, the respondents seemed in general to be skeptical about various aspects of biosimilars. Only 26.4% of the respondents had no specific concerns about biosimilars. Respondents seemed especially skeptical when asked about extrapolation; only 13.1% of the respondents thought the concept of extrapolation made sense. Such concerns may be due to the extrapolation concept being rather difficult to grasp for a lay person with no scientific background. Proper patient education about the various issues concerning biosimilars would possibly decrease suspicions.
Respondents seemed to have more trust in their treating physician than in pharmacists or regulatory agencies. This highlights the importance of a good patient-doctor relationship. Furthermore, 25.1% of the respondents would like patient associations to be informed about matters involving biosimilars and to be able to give their opinions in discussions around biosimilars. Patient organizations could play a key role in informing their members and bring the patient perspective into the discussion concerning biosimilars.
Although there were no statistically significant differences between the responses from Crohn's disease and ulcerative colitis patients, Crohn's disease patients tended to be slightly more skeptical about biosimilars. Crohn's disease patients also tended to have more worries concerning biosimilars in comparison with ulcerative colitis patients.
This survey had several limitations. The survey was self-selective, and because it was only available online and in nine languages, this may have affected the participant population. It may also be possible that some respondents found more than one applicable response option in some questions, but were only able to choose one, which may have affected the results.
In conclusion, our findings show that patients want to be informed and involved. They highlight the need to involve patients in decision-making when starting a biosimilar and in developing the management plan. Informing patients via therapeutic education programs is advisable, and this could be implemented with patient organization support.
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